Krystal Biotech, Inc. KRYS Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s stock issuance proceeds?
- Krystal Biotech, Inc. (KRYS) reported stock issuance proceeds of $6.5M in Q1 2026.
- How has Krystal Biotech, Inc.'s stock issuance proceeds changed year-over-year?
- Krystal Biotech, Inc.'s stock issuance proceeds increased by 344.7% year-over-year, from $1.46M to $6.5M.
- What is the long-term trend for Krystal Biotech, Inc.'s stock issuance proceeds?
- Over 3 years (2021 to 2025), Krystal Biotech, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $355.84M to $0.
- What does stock issuance proceeds mean?
- Cash received from selling company shares to investors or employees.
- How do you interpret stock issuance proceeds?
- High proceeds indicate capital raising activities to fund operations, while low proceeds suggest reliance on internal cash flow.
- How does stock issuance proceeds compare across companies?
- Common for biotech companies to raise capital via equity to fund clinical trials and commercialization.